EATON VANCE MANAGEMENT - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.

Quarter-by-quarter ownership
EATON VANCE MANAGEMENT ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2022$1,334,000
+7.6%
20,4130.0%0.00%0.0%
Q2 2022$1,240,000
-8.5%
20,413
-5.5%
0.00%0.0%
Q1 2022$1,355,000
-17.5%
21,593
-0.3%
0.00%0.0%
Q4 2021$1,642,000
-28.1%
21,663
+0.3%
0.00%
-33.3%
Q3 2021$2,285,000
-34.1%
21,593
+0.8%
0.00%
-40.0%
Q2 2021$3,467,000
+39.4%
21,413
+4.9%
0.01%
+25.0%
Q1 2021$2,487,000
-60.2%
20,413
-50.0%
0.00%
-20.0%
Q4 2020$6,250,000
+266.1%
40,826
+100.0%
0.01%
+66.7%
Q3 2020$1,707,000
+13.8%
20,4130.0%0.00%0.0%
Q2 2020$1,500,000
+73.2%
20,4130.0%0.00%
+50.0%
Q1 2020$866,000
-30.3%
20,4130.0%0.00%0.0%
Q4 2019$1,243,000
+48.5%
20,4130.0%0.00%0.0%
Q3 2019$837,000
-12.9%
20,4130.0%0.00%0.0%
Q2 2019$961,000
+31.8%
20,4130.0%0.00%0.0%
Q1 2019$729,000
+25.0%
20,4130.0%0.00%0.0%
Q4 2018$583,000
-35.6%
20,4130.0%0.00%0.0%
Q3 2018$905,000
-24.5%
20,4130.0%0.00%
-33.3%
Q2 2018$1,199,00020,4130.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2022
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$27,989,04633.20%
Gilfoyle Management LLC 100$4,84215.90%
NEA Management Company, LLC 1,587,854$89,142,1246.80%
ARK Investment Management 7,338,447$411,980,3942.73%
Nikko Asset Management Americas, Inc. 3,533,357$198,327,3282.09%
Del-Sette Capital Management, LLC 33,661$1,889,7291.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Merlin Capital, Inc 8,802$494,1441.67%
Green Alpha Advisors, LLC 34,373$1,929,7001.27%
View complete list of CRISPR THERAPEUTICS AG shareholders